



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 4th day of December, 2003.

By

Janice Denison
(Signature of person mailing)
Janice Denison
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Susan Dobbs, et al. :

APPLICATION NO.: 09/759,841 : Examiner: To be assigned

FILING DATE: 01/12/2001 : Group Art Unit: 1645

TITLE: ASSAY METHODS :

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).


A prompt and favorable response is earnestly solicited.

Date: December 4th, 2003

Respectfully submitted,

Deborah A. Martin
Deborah A. Martin
Attorney for Applicant(s)
Reg. No. 44,222

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-1821



(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER
INITIAL

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Cammack, N., et al., *Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target*, Antiviral Chemistry & Chemotherapy, Vol. 10: 53-62, 1999

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.